Department of Psychiatry and Psychotherapy, Ludwig Maximilian University , Munich , Germany.
Int J Psychiatry Clin Pract. 2014 Jun;18(2):78-85. doi: 10.3109/13651501.2014.890228.
After 10 years of preparation, DSM-5 was published in 2013. This paper will examine the possible effects of DSM-5 on psychiatric diagnosis and psychopharmacotherapy.
DSM-5 was compared with DSM-IV to identify the important changes in psychiatric diagnosis and possible consequences for psychopharmacotherapy.
Contrary to the original plans, DSM-5 did not make radical changes and move towards dimensional diagnosis but preserved the previous categorical system of disorders and a primarily symptom-based descriptive approach. The dimensional approach was only adopted through the introduction of several transnosological specifiers and the option to make symptom- or syndrome-related assessments. The criteria for some disorders were changed, including affective, dependence and schizophrenic disorders, and a few new disorders were added.
The DSM-IV diagnostic system was largely preserved, although some changes were made, primarily in the field of affective disorder and in several criteria sets. The new transnosological specifiers, severity assessments and cross-cutting dimensional assessments may help to individualise treatment.
经过 10 年的筹备,DSM-5 于 2013 年发布。本文将探讨 DSM-5 对精神科诊断和精神药理学治疗可能产生的影响。
将 DSM-5 与 DSM-IV 进行比较,以确定精神科诊断方面的重要变化以及对精神药理学治疗可能产生的后果。
与最初的计划相反,DSM-5 并未进行激进的改变,也未朝着维度诊断方向发展,而是保留了以前的障碍分类系统和主要基于症状的描述性方法。通过引入几个跨疾病specifiers 和进行与症状或综合征相关的评估的选项,才采用了维度方法。一些障碍的标准发生了变化,包括情感、依赖和精神分裂症障碍,并且添加了一些新的障碍。
尽管进行了一些更改,但 DSM-IV 诊断系统在很大程度上得到了保留,主要是在情感障碍领域和几个标准集中。新的跨疾病specifiers、严重程度评估和跨维度评估可能有助于实现个体化治疗。